Advertisement

Precocious Puberty Therapeutic Management: GnRH Analogs Treatment

  • Claire BouvattierEmail author

Abstract

GnRH analog therapy is an effective treatment for central precocious puberty. The therapeutic management of central precocious puberty should be discussed on clinical criteria (rapidly progressive puberty, advance bone age), biological criteria (LH, inhibin B, estradiol), and ultrasound criteria (uterine length, ovarian volume). The optimal timing of treatment discontinuation has not been clearly evaluated. The average age of discontinuation is around 11 years, the physiological age of puberty in girls. Menarche occurs 12–18 months after the end of treatment. Clinical pubertal signs reappear a few months after the end of the treatment. Compromise of adult height, early menarche, and social and behavioral implications is often a concern for these patients.

Keywords

Adult Height Precocious Puberty GnRH Analog Cyproterone Acetate Central Precocious Puberty 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Soriano-Guillen L, Corripio R, Labarta JI et al (2010) Central precocious puberty in children living in Spain: incidence, prevalence, and influence of adoption and immigration. J Clin Endocrinol Metab 95:4305–4313CrossRefPubMedGoogle Scholar
  2. 2.
    Teilmann G, Pedersen CB, Jensen TK et al (2005) Prevalence and incidence of precocious pubertal development in Denmark: an epidemiologic study based on national registries. Pediatrics 116:1323–1328CrossRefPubMedGoogle Scholar
  3. 3.
    Comite F, Cutler GB Jr, Rivier J, Vale WW, Loriaux DL, Crowley WF Jr (1981) Short-term treatment of idiopathic precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. A preliminary report. N Engl J Med 305:1546–1550CrossRefPubMedGoogle Scholar
  4. 4.
    Palmert MR, Malin HV, Boepple PA (1999) Unsustained or slowly progressive puberty in young girls: initial presentation and long-term follow-up of 20 untreated patients. J Clin Endocrinol Metab 84:415–423PubMedGoogle Scholar
  5. 5.
    Klein KO (1999) Precocious puberty: who has it? Who should be treated? J Clin Endocrinol Metab 84:411–414CrossRefPubMedGoogle Scholar
  6. 6.
    Lazar L, Pertzelan A, Weintrob N, Phillip M, Kauli R (2001) Sexual precocity in boys: accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height. J Clin Endocrinol Metab 86:4127–4132CrossRefPubMedGoogle Scholar
  7. 7.
    Prété G, Couto-Silva AC, Trivin C, Brauner R (2008) Idiopathic central precocious puberty in girls: presentation factors. BMC Pediatr 8:27PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Worley G, Houlihan CM, Herman-Giddens ME et al (2002) Secondary sexual characteristics in children with cerebral palsy and moderate to severe motor impairment: a cross-sectional survey. Pediatrics 110:897–902CrossRefPubMedGoogle Scholar
  9. 9.
    Albanese A, Hopper NW (2007) Suppression of menstruation in adolescents with severe learning disabilities. Arch Dis Child 92:629–632PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Resende EA, Lara BH, Reis JD et al (2007) Assessment of basal and gonadotropin-releasing hormone-stimulated gonadotropins by immunochemiluminometric and immunofluorometric assays in normal children. J Clin Endocrinol Metab 92:1424–1429CrossRefPubMedGoogle Scholar
  11. 11.
    Mogensen SS, Aksglaede L, Mouritsen A et al (2011) Diagnostic work-up of 449 consecutive girls who were referred to be evaluated for precocious puberty. J Clin Endocrinol Metab 96:1393–1401CrossRefPubMedGoogle Scholar
  12. 12.
    Neely EK, Wilson DM, Lee PA et al (1995) Spontaneous serum gonadotropin concentrations in the evaluation of precocious puberty. J Pediatr 127:47–52CrossRefPubMedGoogle Scholar
  13. 13.
    Eckert KL, Wilson DM, Bachrach LK et al (1996) A single-sample, subcutaneous gonadotropin-releasing hormone test for central precocious puberty. Pediatrics 97:517–519PubMedGoogle Scholar
  14. 14.
    Carel JC, Eugster EA, Rogol A et al (2009) Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 123:752–762CrossRefGoogle Scholar
  15. 15.
    Chalumeau M, Chemaitilly W, Trivin C et al (2002) Central precocious puberty in girls: an evidence-based diagnosis tree to predict central nervous system abnormalities. Pediatrics 109:61–67CrossRefPubMedGoogle Scholar
  16. 16.
    Chalumeau M, Hadjiathanasiou CG, Ng SM et al (2003) Selecting girls with precocious puberty for brain imaging: validation of European evidence-based diagnosis rule. J Pediatr 143:445–450CrossRefPubMedGoogle Scholar
  17. 17.
    Roger M, Lahlou N, Chaussain JL (1996) Gonadotropin-releasing hormone testing in pediatrics. In: Ranke MB (ed) Diagnosis of endocrine function in children and adolescents. Johann Ambrosius Barth Verlag, Heidelberg, pp 346–369Google Scholar
  18. 18.
    Carel JC, Leger J (2008) Precocious puberty. N Engl J Med 358:2366–2376CrossRefPubMedGoogle Scholar
  19. 19.
    Sehested A, Andersson AM, Müller J, Skakkebaek NE (2000) Serum inhibin A and inhibin B in central precocious puberty before and during treatment with GnRH agonists. Horm Res 54:84–91CrossRefPubMedGoogle Scholar
  20. 20.
    Hagen CP, Sørensen K, Anderson RA, Juul A (2012) Serum levels of antimüllerian hormone in early maturing girls before, during, and after suppression with GnRH agonist. Fertil Steril 98:1326–1330CrossRefPubMedGoogle Scholar
  21. 21.
    Battaglia C, Mancini F, Regnani G et al (2003) Pelvic ultrasound and color Doppler findings in different isosexual precocities. Ultrasound Obstet Gynecol 22:277–283CrossRefPubMedGoogle Scholar
  22. 22.
    De Vries L, Horev G, Schwartz M, Philip M (2006) Ultrasonographic and clinical parameters for early differentiation between precocious puberty and premature thelarche. Eur J Endocrinol 154:891–898CrossRefPubMedGoogle Scholar
  23. 23.
    Haber HP, Wollmann HA, Ranke MB (1995) Pelvic ultrasonography: early differentiation between isolated premature thelarche and central precocious puberty. Eur J Pediatr 154:182–186CrossRefPubMedGoogle Scholar
  24. 24.
    Chemaitilly W, Trivin C, Adan L et al (2001) Central precocious puberty: clinical and laboratory features. Clin Endocrinol (Oxf) 54:289–294CrossRefGoogle Scholar
  25. 25.
    De Sanctis V, Corrias A, Rizzo V et al (2000) Etiology of central precocious puberty in males: the results of the Italian Study Group for Physiopathology of Puberty. J Pediatr Endocrinol Metab 13(Suppl 1):687–693PubMedGoogle Scholar
  26. 26.
    Carel JC, Lahlou N, Roger M, Chaussain JL (2004) Precocious puberty and statural growth. Hum Reprod Update 10:135–147CrossRefPubMedGoogle Scholar
  27. 27.
    Mul D, Bertelloni S, Carel JC et al (2002) Effect of gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty: final height results. Horm Res 58:1–7CrossRefPubMedGoogle Scholar
  28. 28.
    Bertelloni S, Mul D (2008) Treatment of central precocious puberty by GnRH analogs: long-term outcome in men. Asian J Androl 10:525–534CrossRefPubMedGoogle Scholar
  29. 29.
    Klein KO, Barnes KM, Jones JV et al (2001) Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. J Clin Endocrinol Metab 86:4711–4716CrossRefPubMedGoogle Scholar
  30. 30.
    Lazar L, Padoa A, Phillip M (2007) Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity. J Clin Endocrinol Metab 92:3483–3489CrossRefPubMedGoogle Scholar
  31. 31.
    Carel JC, Roger M, Ispas S et al (1999) Final height after long-term treatment with triptorelin slow-release for central precocious puberty: importance of statural growth after interruption of treatment. J Clin Endocrinol Metab 84:1973–1978CrossRefPubMedGoogle Scholar
  32. 32.
    Arrigo T, Cisternino M, Galluzzi F et al (1999) Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty. Eur J Endocrinol 141:140–144CrossRefPubMedGoogle Scholar
  33. 33.
    Paul D, Conte FA, Grumbach MM, Kaplan SL (1995) Long-term effect of gonadotropin-releasing hormone agonist therapy on final and near-final height in 26 children with true precocious puberty treated at a median age of less than 5 years. J Clin Endocrinol Metab 80:546–551PubMedGoogle Scholar
  34. 34.
    Fuqua JS (2013) Treatment and outcomes of precocious puberty: an update. J Clin Endocrinol Metab 98:2198–2207CrossRefPubMedGoogle Scholar
  35. 35.
    Magiakou MA, Manousaki D, Papadaki M et al (2010) The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study. J Clin Endocrinol Metab 95:109–117CrossRefPubMedGoogle Scholar
  36. 36.
    Bouvattier C, Coste J, Rodrigue D et al (1999) Lack of effect of GnRH agonists on final height in girls with advanced puberty: a randomized long-term pilot study. J Clin Endocrinol Metab 84:3575–3578CrossRefPubMedGoogle Scholar
  37. 37.
    Tremblay L, Frigon JY (2005) Precocious puberty in adolescent girls: a biomarker of later psychosocial adjustment problems. Child Psychiatry Hum Dev 36:73–94CrossRefPubMedGoogle Scholar
  38. 38.
    Copeland W, Shanahan L, Miller S et al (2010) Outcomes of early pubertal timing in young women: a prospective population-based study. Am J Psychiatry 167:1218–1225PubMedCentralCrossRefPubMedGoogle Scholar
  39. 39.
    Johansson T, Ritzén EM (2005) Very long-term follow-up of girls with early and late menarche. Endocr Dev 8:126–136CrossRefPubMedGoogle Scholar
  40. 40.
    Lahlou N, Carel JC, Chaussain JL, Roger M (2000) Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J Pediatr Endocrinol Metab 13(Suppl 1):723–737PubMedGoogle Scholar
  41. 41.
    Carel JC, Lahlou N, Jaramillo O et al (2002) Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg). J Clin Endocrinol Metab 87:4111–4116CrossRefPubMedGoogle Scholar
  42. 42.
    Carel JC, Blumberg J, Seymour C et al (2006) Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty. Eur J Endocrinol 154:119–124CrossRefPubMedGoogle Scholar
  43. 43.
    Neely EK, Hintz RL, Parker B et al (1992) Two-year results of treatment with depot leuprolide acetate for central precocious puberty. J Pediatr 121:634–640CrossRefPubMedGoogle Scholar
  44. 44.
    Mul D, Hughes IA (2008) The use of GnRH agonists in precocious puberty. Eur J Endocrinol 159(Suppl 1):S3–S8CrossRefPubMedGoogle Scholar
  45. 45.
    Partsch CJ, Sippell WG (2002) Treatment of central precocious puberty. Best Pract Res Clin Endocrinol Metab 16:165–189CrossRefPubMedGoogle Scholar
  46. 46.
    Manasco PK, Pescovitz OH, Blizzard RM (1993) Local reactions to depot leuprolide therapy for central precocious puberty. J Pediatr 123:334–335CrossRefPubMedGoogle Scholar
  47. 47.
    Palmert MR, Mansfield MJ, Crowley WF Jr et al (1999) Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty. J Clin Endocrinol Metab 84:4480–4488PubMedGoogle Scholar
  48. 48.
    Feuillan PP, Jones JV, Barnes KM et al (2000) Boys with precocious puberty due to hypothalamic hamartoma: reproductive axis after discontinuation of gonadotropin- releasing hormone analog therapy. J Clin Endocrinol Metab 85:4036–4038CrossRefPubMedGoogle Scholar
  49. 49.
    Seminara S, Nanni L, Generoso M et al (2000) Effect of treatment with cyproterone acetate on uterine bleeding at the beginning of GnRH analogue therapy in girls with idiopathic central precocious puberty. Horm Res Paediatr 73:386–389CrossRefGoogle Scholar
  50. 50.
    Heger S, Müller M, Ranke M et al (2006) Long-term GnRH agonist treatment for female central precocious puberty does not impair reproductive function. Mol Cell Endocrinol 25:254–255Google Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Bicêtre hospital and Paris Sud universityLe Kremlin-BicêtreFrance

Personalised recommendations